Member Info for dactions

It's better news than one could have hoped for given the low SP. There is every sign they can keep up this progress and we can expect a re-rating of the shares.

Chris Gilbert told me at the London investor show last month that they can sell everything they produce - he was quite clear about that because he repeated the word "everything"

The more I think about it and especially following SoH's presentation at the Westminster Investor show last month and his enthusiasm when speaking with me personally on the sweetbiotix granules he had there, the more I can see a spin-off of the Sweetbiotix side coming. SoH is understandably feeling very confident of the way the AIM market is working after he spun-off Skinbiotics - I feel sure that is in his mind and today's RNS only serves to convince me that is what is likely to happen. He build up the value in each separate division, sells them off for a shared profit whilst retaining a large stake. Either way Opti benefits.

I read this morning's RNS as to say "Look guys we're doing something - yes we know you were expecting fireworks in SE Asia but it is still going to happen and soon" Hardly a needed RNS

Just listened to yesterday's interview - SoH's news management skills are amazing re. today's announcement for Sweetbiotix. Could this lead to a sell-off like Skin ?

Well we've finished the day in the blue and I must say I am surprised. Whatever happens tomorrow, it was going to be today that was most concerning with a relatively good discount being given to the Placees. Hopefully, the new shares are in safe long-term hands.

I think I'm with Boyzee if I've understood him correctly. I had a long conversation with SoH at the London Investor show last month and following that conversation, a placing was the last thing I was expecting. I can see the logic but I'm mindful of the share price.

The Edison Research page is here: http://www.edisoninvestmentresearch.com/research/report/reneuron-group580520/full The AIM market has changed in recent years with often little value given to a company's prospects - investors wanting instead regular and growing profits which research biotech companies such as Rene have no chance any more. But that said, and I am a LTH (unfortunately), the BOD has to accept their amateurish competence when it comes to promoting their company. It's not a case of hindsight either because this board has consistently tried to draw attention to their lapses. This is a pity - as the areas of clinical research offer much for patients having little hope at the moment - and needs a strong company to get through to the successful conclusion of Trials III

The paradox that is Rene continues. Edison Research, which is well respected, has updated their opinion of Rene's worth following the Capital day the company ran to promote its involvement in Exosomes. Edison continues to forecast a high sp valuation - adjusting for the 100 for 1 shares change, gives a value of 874p - which underlines the lunacy of the current sp. They also confirm there is sufficient cash to see it through into 2020 before which the current trials will have shown success or not. So, there is massively more cash in the company than the current share price with no value whatsoever on the possibility of successful trial outcomes - current stages showing positive results. QUOTE: A new (existing) platform emerges ReNeuron�s capital markets day showcased its exosome nanomedicine platform. ReNeuron�s scientists, clinicians and its collaborators described the origin and functions of these naturally occurring sub-cellular vesicles. ReNeuron has been working on exosomes for many years since discovering them as a by-product of its genetically modified human neural stem cell line (CTX). The expert panel also described the potential use and applications of exosomes. From oncology therapeutics to drug delivery Through the development of ReNeuron�s CTX cell line products for chronic stroke and retinitis pigmentosa (which continue to advance in clinical studies), applications for the exosome nanomedicine platform have become apparent. Native exosomes migrate to the liver if injected intravenously in healthy animals and to the lymph nodes if injected intraperitoneally. Exosomes also migrate to tumours, opening up the possibility of a targeted cancer therapy because exosomes can be loaded with chemotherapeutic agents, and also oncology diagnostics. New drugs such as mRNAs need a delivery mechanism to protect them from degradation. The loading of exosomes with drugs can both stabilise a labile drug and target its delivery. Thus, the exosome platform could at the very least provide ReNeuron with a source of licensing revenue and at most, a new therapeutic oncology product. Valuation: Minor changes ahead of FY results In recent publications of Edison Healthcare Insight, we increased our estimated FY19 R&D expenses to account for the conduct of two Phase II studies. Since then, we have made one change to our model incorporating our estimate of the FY18 cash. Our risk-adjusted NPV valuation of ReNeuron is �276m, or 8.74p per share (previously �290m). Reneuron�s market capitalisation is c �22m � below cash and ascribing no technology value for a company in two Phase II studies or the recently disclosed exosome platform. This may make our assumption of an injection of funding prior to the end FY19 of increasing significance. End Quote.

Interesting - a nicely timed �25k shares purchase yesterday !?!

I liked the RNS this morning with a business link to US Micropore.Inc. They're a relatively new US company with sales around $10millions according to one site I searched. I don't profess to understand Adsorbent technology (apart from a simple example of using activated carbon to extract misting in double-glazed windows) but Micropore's patent must offer exceptional technical attributes to cleaning air systems useful for TPG. This is an area of high technology engineering - just what TPG is becoming more specialised in. I feel very happy to learn about this business link - it has to be good for both companies. This is what Micropore's website shows about them: Quote: Micropore was founded in March of 1997. Micropore manufactures reactive plastics which incorporate various powders into a molded matrix. The company's first product uses a CO2 adsorbent powder which is formed into a cartridge to create a revolutionary CO2 adsorbent system used in rebreathing and life support applications. The patented technology is the first major advance in CO2 adsorbent technology in over 100 years, providing superior performance advantages over existing granular adsorbents. The CO2 adsorbent cartridges are marketed under the ExtendAir brand name and are used for life support in the fire-fighting, medical, dive, submarine and military markets.End quote.

I'd be surprised Courtier if the greater percentage of shareholders weren't also under water on this share so you're not alone. It's always uncomfortable when you can't buy in at the bottom or sell out at the top - only a few lucky people achieve that. Coro will come good.

I read through the lengthy statement - there is some repetition but if some readers look on it as 'waffle' I can sympathise. However, Optibiotix is on the very cusp of a financial turnaround - profits will start coming in during the next few months - I think that can almost be guaranteed. Look at the value of the Companies/Corporations they've signed deals with ! One paragraph stood out for me on the great prospects for Opti: Quote: The Board believes OptiBiotix is at the leading edge of one of the hottest areas of healthcare innovation which is forecast to become one of the world's fastest growth areas. Over the last 12 months, we have continued our progress of building a broad based microbiome business with a strategy which best maximizes the value in each division and a diversity of IP and commercial relationships which provides shareholders with multiple opportunities. The next stage of the process involves the continued development of new application areas and extending our products into new territories and application areas, such a biotherapeutics, with suitable partners. We believe the Company has now significantly de-risked scientific, clinical and manufacturing risk across its platforms. This changes the risk reward ratio leading to an increase in value and the Company and its assets becoming an attractive proposition for corporate partners. This has led to a number of approaches from potential acquirers interested in assets in specific divisions. End quote.

I understand from a BOD member that the sp fall started last year around 18p by a single large Asian investor. He required funds for tax payments. He did not discuss it with the BOD who might have been able to arrange an orderly sale. Instead, he acted independently - put in place stop-losses with his broker - but each time his sale led to breaching the stop-loss and led to the steady losing spiral that we saw.

I think the BOD will look at the market's reactions to their RNS today with disappointment. They may even be frustratingly surprised. But they shouldn't be - because so much has been promised by the company for far too long. If this is indeed the turning point, then that's a great achievement but it'll take more regular progress updates to convince the market.

Having held these for a number of years, I do think the SP is too low but it will need some good financial news to move it up right now. Did anyone go to the Investor show at Westeminster last month ? I went - and OBT had a big presence but they weren't involved in any specific share meetings either as a breakout or on the main stage as they were last year. That said I spoke at length with the deputy chairman (Woods ?) and he said that the substantial sp drop should have never happened but couldn't reveal anything specific financially other than whatever the audited figures that come out, he is very confident the real trading picture is excellent. I'm not sure what to make of that but we'll see soon enough. However, re the sp drop over recent months, I do believe there was one big asian seller who needed capital for tax liabilities and the price fall sparked off a spiral which was self-feeding.

I think I can understand some of the negative posts - whether they match my background I don't know, but as a LTH since early 2013 I remember coming in around 65p following a positive broker report. All the facts were much as they are now and I couldn't understand the drift to a low near 16p (?) nor could I understand why the loss of interest in a license by C & D. Nor Barder's lack of clarity on that broken deal. There's only so much one can invest and I couldn't afford to add more at the low points so it gets a bit difficult to watch the SP's gyrations over such a long period if you're not trading them. I added though at 38p last year but then saw it fall to around 22p. So, for me that's 5 years investing in a sure thing and well down to boot. I remain optimistic and don't intend to sell and hope if good news does come I can hold myself to that promise.

I’d like to think we’ll soon find out and it’s really positive this time. They give me the impression of keep changing their business approach. Since Reid took over lead, they do seem more assured but good financials are still needed.

Thanks Trurotrader for comments. There’s firmness in the sp on light buys/sells perhaps acquisition news is in the offing ?

Malkis - quite agree with you. The website in effect has no content and is frankly very unprofessional. It hardly adds any weight to the company. Come on James Menzies - get a grip - it's looking like a 'kiddies' plaything !